$NVS $INCY received FDA approval for its drug to treat patients with a tough-to-treat form of lung cancer. $INCY is eligible to receive over $500 million in milestones &amp;royalties 

$NVS beats Pfizer Inc $PFE in the race to develop a treatment for this specific form of lung cancer